Abstract
Involuntary movements--or dyskinesias--are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients. Despite the importance of this problem, little was known about the cause of dyskinesia until recently; however, this situation has changed significantly in the past few years. Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antiparkinson Agents / adverse effects*
-
Basal Ganglia / drug effects*
-
Basal Ganglia / pathology
-
Basal Ganglia / physiopathology
-
Disease Models, Animal
-
Dopamine / metabolism*
-
Dyskinesia, Drug-Induced / drug therapy
-
Dyskinesia, Drug-Induced / pathology
-
Dyskinesia, Drug-Induced / physiopathology*
-
Humans
-
Levodopa / adverse effects*
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / pathology
-
Parkinson Disease / physiopathology
Substances
-
Antiparkinson Agents
-
Levodopa
-
Dopamine